Researchers discovered a novel molecular target for the design of drugs which could be safer and more effective for multiple sclerosis, as well as other disorders associated with the loss of white matter in the brain.
Researchers have discovered a way in which the body can remove injured axons. They also identified a potential target for new drugs which could prevent the inappropriate loss of axons, as well as maintain nerve function.
Monitoring progenitor cells in the brains of living mice, researchers discover these cells remain highly dynamic in the adult brain. Progenitor cells can transform into cells that insulate nerve fibers and help form scars that aid in tissue repair, study suggests.
A population based study which looked at patients newly diagnosed with MS discovered African-Americans had a 47% increased risk of developing the disease compared with Caucasians. However, Hispanic and Asian people had a 58 and 80% lower risk.
Using several imaging methods, researchers note chronic cerebrospinal venous insufficiency, CCSVI, occurs in low rates for patients with multiple sclerosis and non-MS volunteers.
Using MRI scans on patients with multiple sclerosis and associated cognitive problems, researchers noted extra white matter dysfunction in areas important for cognitive skills.
Researchers discover proteins in the IL-6 signaling pathway may be leveraged as novel biomarkers of multiple sclerosis (MS) to gauge disease activity and as a target for new therapies.
Researchers suggest obesity may increase the risk of developing multiple sclerosis (MS) in children and teenage girls. The study found the risk was one and a half times higher in overweight girls.
Researchers report that the protein Klotho plays an important role in the health of myelin, the insulating material allowing for the rapid communication between nerve cells. These findings may lead to new therapies for multiple sclerosis (MS) and Alzheimer’s disease (AD).
Scientists report researchers are now on the threshold of human application of stem cell therapies for a class of neurological diseases known as myelin disorders – a long list of diseases that include conditions such as multiple sclerosis, white matter stroke, cerebral palsy, certain dementias, and rare but fatal childhood disorders called pediatric leukodystrophies.